Blood-thinning drugs designed to cut stroke risk may actually increase it

Scientists call for caution in prescribing anticoagulants after some patients with other conditions found to suffer more strokesBlood-thinning drugs may increase rather than cut the risk of stroke in some people over 65 who have an irregular heartbeat and also chronic kidney disease, according to a new study.The researchers are calling on doctors to be more cautious in prescribing the drugs, called anticoagulants, until there has been more research.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Medical research Stroke Drugs Health Science Society Doctors Source Type: news

Related Links:

Authors: Tajti P, Karatasakis A, Danek BA, Alaswad K, Karmpaliotis D, Jaffer FA, Choi JW, Yeh RW, Patel M, Mahmud E, Burke MN, Krestyaninov O, Khelimskii D, Toma C, Doing AH, Uretsky B, Koutouzis M, Tsiafoutis I, Wyman RM, Garcia S, Holper E, Xenogiannis I, Rangan BV, Banerjee S, Ungi I, Brilakis ES Abstract OBJECTIVES: The effect of chronic kidney disease (CKD) on in-hospital outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study. METHODS: We evaluated the prevalence of CKD and its impact on CTO-PCI outcomes in 1979 patients who underwent 2040 procedures b...
Source: The Journal of Invasive Cardiology - Category: Cardiology Tags: J Invasive Cardiol Source Type: research
CONCLUSIONS: An elevated RDW is associated with a worse outcome following valve surgery. The predictive ability of the RDW, when assessed by the area under the ROC curve, improved the predictive ability of the EuroSCORE II calculator. PMID: 30207123 [PubMed - in process]
Source: Journal of Heart Valve Disease - Category: Cardiology Tags: J Heart Valve Dis Source Type: research
In conclusion, the use of third-generation P2Y12 inhibitors among non-CKD patients was associated with better outcomes. CKD patients receiving third-generation P2Y12 inhibitors treatment showed no statistically significant lower mortality and thrombotic events. Bleeding risk was not increased with the use of third-generation P2Y12 inhibitors in either group of patients. PMID: 30207603 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: J Clin Pharmacol Source Type: research
Abstract Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease characterized by thickened, red, scaly plaques and systemic inflammation. Psoriasis is also associated with multiple comorbid conditions, such as joint destruction, cardiovascular disease, stroke, hypertension, metabolic syndrome, and chronic kidney disease. The discovery of IL-17-producing T cells in a mouse model of autoimmunity transformed our understanding of inflammation driven by T lymphocytes and associations with human inflammatory diseases, such as psoriasis. Under the regulation of IL-23, T cells that produce high l...
Source: Journal of Immunology - Category: Allergy & Immunology Authors: Tags: J Immunol Source Type: research
ConclusionIn this explorative study analyzing patients with severe CKD treated with edoxaban 30  mg once daily, no major bleeding or thrombotic events were observed. Some minor bleedings were observed. While additional studies are necessary to confirm the results of this exploratory study, edoxaban 30 mg once daily appears to be safe in patients with severe CKD.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
AbstractPurposeA timely pharmacoinvasive strategy consisting of thrombolytic therapy (TT) plays a pivotal role in three major scenarios: acute ischemic stroke (AIS), acute myocardial infarction (STEMI), and massive pulmonary embolism (PE). Presence of advanced chronic kidney disease (CKD) (estimated glomerular filtration rate
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
AbstractIndividuals with diabetes mellitus exhibit an increased propensity to develop cardiovascular disorders such as coronary artery disease, stroke and heart failure. Over recent decades, numerous cardiovascular outcome trials in individuals with type 2 diabetes have been published, with data showing a reduction of cardiovascular morbidity and mortality by sodium –glucose cotransporter 2 (SGLT2) inhibitors. These results not only provide novel therapeutic options for this high-risk population but also advance our current understanding of cardiovascular risk reduction in diabetes. The current overview article summa...
Source: Diabetologia - Category: Endocrinology Source Type: research
Publication date: Available online 28 August 2018Source: Canadian Journal of CardiologyAuthor(s): David Massicotte-Azarniouch, John Paul Kuwornu, Megan K. McCallum, Nisha Bansal, Ngan Lam, Amber O. Molnar, Patrick Pun, Deborah Zimmerman, Amit X. Garg, Manish M. SoodABSTRACTBackgroundThe risks and subsequent outcomes of syncope among seniors with chronic kidney disease (CKD) are unclear.MethodsWe conducted a population-based retrospective cohort study of 272,146 patients ≥66 years old in Ontario, Canada from April 1st 2006 to March 31st 2016. Using administrative healthcare databases we examined the association of estima...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Conditions:   Chronic Kidney Diseases;   Heart Attack;   Stroke, Ischemic Interventions:   Drug: Ticagrelor 90mg;   Drug: Clopidogrel 75mg;   Drug: Aspirin 81 mg Sponsors:   University of Arkansas;   American Society of Nephrology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Kidney Disease | Research | Science | Stroke | Study | Urology & Nephrology